Owkin’s Post

Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist from Idorsia that will enter Phase 1 trials in early 2025. Our cutting-edge AI engines will maximize its probability of success by identifying the optimal indication and patient sub-population and de-risk its ongoing clinical development. Discover our Tx and Dx pipeline at owkin.com/pipeline

🚲 It’s time for 'A Few of Our Favorite Things' — Meet our Owkinaute Alec Davi and his custom-built bike. Complete with a shark attack seat and a quirky broken bell, this unique ride turns heads wherever it goes. Learn more about Owkin, and what makes us so special: https://lnkd.in/ekqghTTp #LifeAtOwkin

It’s amazing what can be done in just 5 months! Congratulations to the Bioptimus team for the release of H-optimus-0, the world’s largest open-source AI foundation model for pathology. 🧬 We’re excited to use this model to accelerate our diagnostics and drug discovery and development work. Learn more at: https://lnkd.in/gsZEHEx3

🎬 Watch MSIntuit® CRC in action — discover its capabilities, features and functionalities, with comprehensive insights for microsatellite instability (MSI) testing. MSIntuit® CRC is a CE-marked AI diagnostic that provides a MSI prescreen approach with digital pathology. Learn more about MSIntuit CRC https://lnkd.in/gy5ubAZs

🌐 Join us today at the STAT webinar where our Chief Diagnostics Officer, Meriem Sefta, will speak on a panel discussion 'Is this the era of AI diagnostics?' alongside Kunal Chokshi and Gazala Khan. The webinar will be held on July 9th from 5:00 to 5:30 pm CEST. Register today https://lnkd.in/e3rTcATx

Owkin has expanded its footprint into the DACH regions, partnering with nine hospitals in Germany, Switzerland, and Austria. Owkin will bring its world-class data access and AI to the forefront of drug discovery and development, analyzing multimodal patient data in a privacy-enhanced way. Learn more here: https://lnkd.in/ePAwi_Q7

Did you know that there is a simple and standardized approach to detect TLS across tumor types from digital H&E slides? With a sensitivity of 97%, TLS Detect has the potential to screen for TLS presence in tumors in a research setting. Help us understand your needs for TLS detection in your research by filling out our quick survey 🏆 First five people to complete the 5-question survey will receive a “Humanity” book. Fill out the survey https://lnkd.in/eiPsY_dq

Introducing TLS Detect RUO – an AI research tool designed to detect the presence of tertiary lymphoid structures (TLS) across various tumor types using digital H&E slides. TLS is a novel biomarker for assessing survival risk and immunotherapy response in untreated cancer patients. With a sensitivity of 97%, TLS Detect screens for TLS presence in tumors in a research setting. TLS Detect was developed with annotated data from Cancer Comprehensive Center and long-time partner of Owkin, Institut Bergonié. Visit the TLS Detect product page https://lnkd.in/eBqzUt23 Help us understand the needs of TLS detection in your research https://lnkd.in/eiPsY_dq #tertiarylymphoidstructures #tls

Owkin’s AI is accelerating and augmenting biology: This month, we’re exploring how Owkin is augmenting #biology with PACpAInt – our #AI model to identify subtypes of pancreatic adenocarcinoma from whole slide digital images. 👇 The AI model robustly predicts the known ‘classical’ and ’basal’ subtypes, which can accelerate how doctors choose the best treatment options for every patient. PACpAInt also identified two novel ‘mixed’ and ‘intermediate’ subtypes, highlighting important heterogeneity within the tumour, which paves the way to new therapeutic strategies in the future. Take a look at the original publication: https://lnkd.in/echG-6Q7